Single-cell dissection of tumor microenvironmental response in CTCL: Durvalumab combined with lenalidomide drives superior immunomodulation compared to single-agent durvalumab

IF 7.1 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2025-10-01 DOI:10.1016/j.ejca.2025.115813

Christiane Querfeld MD, PhD, Hanjun Qin PhD, Ching-Yu Su, Zhen Han PhD, Jasmine Zain MD, Steven T. Rosen MD, Xiwei Wu PhD

引用次数: 0

查看原文本刊更多论文

CTCL中肿瘤微环境反应的单细胞解剖：与单药Durvalumab相比，Durvalumab联合来那度胺驱动更好的免疫调节

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.